Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

- Dowsett, M., Forbes, J. F., Dubsky, P., Gnant, M., Kaufmann, M., Kilburn, L., Perrone, F., Rea, D., Thuerlimann, B., van de Velde, C., Pan, H., Peto, R., Bradley, R., Ingle, J., Aihara, T., Bliss, J., Boccardo, F., Coates, A., Coombes, R. C., Cuzick, J.

Interpreting clinical evidence

- Freemantle, Nicholas, Eastaugh, Joanne, Calvert, Melanie, Hill, Suzanne, Berlin, Jesse

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials

- Bernhard, Jürg, Luo, Weixiu, Pavesi, Lorenzo, Parmar, Vani, Regan, Meredith M., Pagani, Olivia, Fleming, Gini F., Francis, Prudence A., Price, Karen N., Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Ribi, Karin, Walley, Barbara A., Colleoni, Marco, Burstein, Harold J., Tondini, Carlo, Pinotti, Graziella, Spazzapan, Simon, Ruhstaller, Thomas, Puglisi, Fabio

Utility of adjuvant systemic therapy in melanoma

- Eggermont, A. M. M., Testori, A., Marsden, J., Hersey, P., Quirt, I., Petrella, T., Gogas, H., Mackie, R. M., Hauschild, A.